MediWound Ltd. (NASDAQ:MDWD) Receives $32.25 Average PT from Analysts

Shares of MediWound Ltd. (NASDAQ:MDWD) have been assigned a consensus recommendation of “Hold” from the six brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $32.25.

Several research analysts have recently commented on MDWD shares. Wall Street Zen downgraded MediWound from a “hold” rating to a “sell” rating in a research note on Friday, July 18th. Zacks Research cut shares of MediWound from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a report on Wednesday, October 8th.

MediWound Stock Down 0.7%

NASDAQ:MDWD opened at $18.03 on Tuesday. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50. The firm has a market capitalization of $199.90 million, a price-to-earnings ratio of -6.83 and a beta of 0.22. The stock’s 50 day moving average price is $17.83 and its two-hundred day moving average price is $18.82.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.68). MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.The firm had revenue of $5.71 million for the quarter, compared to the consensus estimate of $5.68 million. Equities research analysts expect that MediWound will post -2.66 EPS for the current year.

Institutional Trading of MediWound

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDWD. Rhumbline Advisers boosted its position in MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 481 shares during the period. Russell Investments Group Ltd. grew its stake in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares during the last quarter. Corebridge Financial Inc. boosted its holdings in MediWound by 17.1% during the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 665 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in MediWound by 14.8% in the 1st quarter. Bank of New York Mellon Corp now owns 18,357 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 2,370 shares during the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.